

Embargoed: 0700hrs, 3 April 2008

**Akers Biosciences, Inc.**  
("ABI" or the "Company")

**ABI Names Thomas A. Nicolette CEO**

ABI, the developer, manufacturer and supplier of rapid diagnostic testing equipment, announces the appointment of a new Chief Executive Officer and other changes to its Board.

Having successfully begun the execution of the Company's transition of emphasis from R&D into volume sales of its core products over the past twelve months, Thomas A. Nicolette has become CEO of ABI with immediate effect. Dr. Raymond F. Akers Jr., following a period of 12 years as Chief Executive Officer during which he has brought forward, from concept through to completion, the 6 platform technologies that form the basis of the ABI's commercial offering today, will now hold the position of Executive Vice Chairman of the Board. He will continue to lead the development of new products and technical support of ABI's existing product portfolio.

Robert J. Paratore, who has served as a senior member of the finance department of ABI for 6 years, latterly as its Financial Controller, has been promoted to Chief Financial Officer.

**Thomas A. Nicolette, President & CEO, commented,**

"These changes to the structure of the Board reflect the progress over the past year in which we have successfully identified and delivered sustainable routes to market of our products, up-scaled our marketing efforts worldwide and appointed one of the UK's leading investment banks for growth companies. We believe we now have the right team positioned to drive ABI forward to deliver investors the most value from over a decade of product development."

The Company will publish its financial results for 2007 on Monday 7 April 2008.

**Enquiries:**

Thomas A. Nicolette  
President and CEO  
Tel. +1 856 848 8698

Ben Simons or Eleanor Williamson  
M:Communications  
Tel. +44 (0)20 7153 1540

Alasdair Younie  
Arbuthnot Securities Limited  
Tel. +44 (0)20 7012 2139